This potent ATP-competitive pan-Pim kinase inhibitor has activity against a broad range of hematologic malignancy cell lines including Pim-2-dependent MM.72 LGB321 was identified during a screen for pan-Pim inhibitors and selected for further development because of a relative potency for inhibiting Pim-2 with its lower Km for ATP.16 Mechanistic studies indicate its cytotoxic anti-MM effect is mediated by inhibition of mTORC1 signaling and BAD phosphorylation.72 LGB321 was effective in a Pim-2-dependent MM xenograft model.1 To date, LGB321 has not entered clinical development. This evidence concerns the gene BAD and Miyoshi myopathy.